PL PLNT Planet Fitness, Inc. Loading... : Bullish and Bearish Analyst Opinions

Planet Fitness cuts outlook on weak sign-ups

Planet Fitness lowers its profit outlook as the company invests in marketing and adjusts.

Canaccord Genuity raises its price target on Planet Fitness to 82 dollars from 80 dollars.

Mass gym contradicts luxury exclusivity trade.

Barbarian Capital highlights a rough earnings season for former growth darlings in staples.

Barbarian Capital mentions they were looking at Planet Fitness yesterday but provides no.

Planet Fitness is criticized for billing issues and uncancellable memberships.

Bearish view on PLNT due to hundreds of FTC complaints about billing fraud and uncancellable.

Edwin Dorsey highlights The Bear Cave's early warnings on Planet Fitness billing fraud.

Edwin Dorsey highlights ongoing problems at Planet Fitness.

Net joins declined, leading to a 2026 guidance cut and suspension of the Black Card price hike; expansion continues despite weak demand. Negative operational metrics (declining memberships, halted pricing power) suggest further downside risk, especially after a prior high valuation. The stock is under pressure from fundamental weakness, and the author’s doubt about a rebound aligns with a short-term bearish bias. A surprise improvement in next quarter’s sign-ups or a broader market rally in fitness/consumer stocks could invalidate the short.

Short Planet Fitness as the short leg of a GLP-1 pair trade.

The tweet reports a day of significant double-digit declines in consumer staples.

Planet Fitness beat Q4 earnings but provided soft guidance for 2026 due to a "transition year" involving equipment revenue pushouts. While the price hike to $15 is working, the intentional delay in equipment revenue to support franchisees creates a temporary earnings hole. The stock is likely dead money until the transition yields clear results. NEUTRAL. If membership growth slows alongside the equipment revenue pause, the stock could re-rate lower.

Spevak explicitly states that the rise of GLP-1 drugs has been the "complete opposite" of a death knell for gyms. He notes that users are realizing they need "lifestyle change" and resistance training to avoid side effects (muscle loss). The market initially feared GLP-1s would make gyms obsolete. Spevak's data suggests a symbiotic relationship: as LLY/NVO sell more drugs, the "prescription" increasingly includes strength training. This benefits gym operators (LTF is the closest public proxy to Equinox's luxury tier; PLNT captures the mass market). Long the drug makers (LLY, NVO) and the gym operators (LTF, PLNT) as a combined "health span" trade. High valuation of GLP-1 stocks; potential for gym churn if economic conditions worsen for the aspirational class.